Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Operating Leases (2019 - 2025)

Harvard Bioscience (HBIO) has disclosed Operating Leases for 7 consecutive years, with $8.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases rose 12.58% to $8.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.8 million, a 12.58% increase, with the full-year FY2024 number at $7.5 million, up 21.4% from a year prior.
  • Operating Leases was $8.8 million for Q3 2025 at Harvard Bioscience, roughly flat from $8.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $9.2 million in Q1 2021 to a low of $4.6 million in Q1 2024.
  • A 5-year average of $7.3 million and a median of $7.4 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: plummeted 35.72% in 2022, then skyrocketed 58.66% in 2025.
  • Harvard Bioscience's Operating Leases stood at $6.5 million in 2021, then increased by 14.32% to $7.4 million in 2022, then decreased by 16.27% to $6.2 million in 2023, then increased by 21.4% to $7.5 million in 2024, then grew by 16.97% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Operating Leases are $8.8 million (Q3 2025), $8.8 million (Q2 2025), and $7.2 million (Q1 2025).